Cannabis and Social Anxiety Disorder
What the evidence actually says about using cannabis, CBD, and THC for social anxiety — and where the science is still thin.
Social anxiety is one of the few anxiety conditions where cannabis research has produced a real signal — but almost entirely for CBD, not THC, and mostly in small short-term studies. High-THC flower is a coin flip: it calms some people and triggers panic in others, and regular use is linked to worse anxiety over time. If you're self-medicating with daily high-THC products and your social anxiety is getting worse, that's a known pattern, not bad luck.
Not medical advice
This article is not medical advice. It summarizes published research so you can have a better conversation with a clinician. Social anxiety disorder is a treatable condition with well-studied first-line therapies. If cannabis is interacting with your mental health — in either direction — talk to a doctor, ideally one who won't dismiss the question.
Plain-language summary
Social anxiety disorder (SAD) is a persistent fear of social situations where you might be judged. It affects roughly 7% of U.S. adults in a given year [1].
The cannabis evidence breaks into three buckets:
- CBD (cannabidiol), taken acutely at moderate-to-high doses (300–600 mg), reduces anxiety during simulated public speaking in small randomized trials — including one in people with diagnosed SAD Weak / limited [2][3].
- THC has a biphasic effect: low doses can reduce anxiety, higher doses reliably increase it Strong evidence [4]. For socially anxious people specifically, regular cannabis use is associated with worse long-term outcomes Strong evidence [5].
- Whole-plant, real-world cannabis use for SAD has essentially no controlled trial data. Surveys show many people with SAD use cannabis to cope, and this group has higher rates of cannabis use disorder than the general population Strong evidence [5][6].
What probably works
Nothing in cannabis meets the bar of 'probably works' the way SSRIs or CBT do for SAD. The closest candidate is acute oral CBD.
- Acute oral CBD, 300–600 mg, before a feared social situation. Bergamaschi et al. (2011) gave 24 treatment-naive SAD patients 600 mg CBD or placebo before a simulated public speaking test. The CBD group had significantly less anxiety, cognitive impairment, and discomfort during the speech [2]. Zuardi et al. (2017) found 300 mg was the effective dose in a healthy-volunteer dose-response study, with 100 mg and 900 mg not significantly different from placebo [3]. [evidence:weak — small samples, single-dose designs, no long-term outcomes]
This is the strongest cannabis-related finding in SAD, but 'strongest' here means roughly 50 patients across two trials. It is not on the same evidence footing as established treatments.
What might work
- Chronic CBD dosing. An open-label trial in Japanese teens with social anxiety found 300 mg/day CBD for 4 weeks reduced symptoms Weak / limited [7]. No placebo arm, small sample.
- Low-dose THC in controlled settings. Childs et al. (2017) showed 7.5 mg oral THC reduced subjective stress in a stress task in healthy adults, while 12.5 mg worsened it Weak / limited [4]. Whether this generalizes to SAD patients in real social situations is untested.
- CBD-dominant flower or oils. Plausible by extrapolation from isolated CBD trials, but the doses people actually consume from flower (often <50 mg CBD) are well below the 300–600 mg used in studies. No data
What doesn't work, or shows evidence of harm
- High-THC cannabis as a regular coping tool. Buckner and colleagues have shown across multiple studies that people with SAD who use cannabis to cope have higher rates of cannabis use disorder and worse anxiety over time Strong evidence [5][6]. This is one of the more consistent findings in the field.
- Cannabis to manage anticipatory anxiety before specific events (dating, presentations). No controlled evidence supports this, and the acute panic risk with high-THC products is well documented Strong evidence [4].
- The 'indica calms anxiety' folklore. Indica vs. sativa labeling does not reliably predict chemistry or effects, and there is no evidence it predicts anxiolytic response. [evidence:none — marketing folklore]
- Specific terpene claims (e.g., 'myrcene above 0.5% sedates,' 'linalool is anxiolytic in flower'). Terpenes have pharmacological activity in isolation at high doses, but evidence that inhaled terpene levels in flower meaningfully alter anxiety in humans is absent. No data
What we don't know
- Whether inhaled CBD-dominant flower produces effects comparable to 300+ mg oral CBD.
- Whether CBD helps SAD when taken daily over months (the trials are days to weeks).
- Whether CBD interacts usefully — or dangerously — with SSRIs, the standard SAD medication. CBD inhibits CYP enzymes that metabolize many psychiatric drugs Strong evidence [8].
- Whether THC:CBD ratios in real-world products produce different SAD outcomes than isolated CBD.
- Whether minor cannabinoids (CBG, CBC) contribute anything. No human SAD data exist.
How this compares to standard treatments
First-line treatments for SAD have decades of replicated evidence:
- Cognitive behavioral therapy (CBT), particularly exposure-based CBT, produces durable symptom reduction with effect sizes around 0.6–0.8 in meta-analyses Strong evidence [9].
- SSRIs and SNRIs (paroxetine, sertraline, venlafaxine) are FDA-approved for SAD with robust trial data Strong evidence [10].
The largest CBD trial in SAD enrolled 24 patients for one session. The largest SSRI trials enrolled thousands over months. These are not comparable evidence bases. CBD may turn out to be a useful adjunct; it is not currently a substitute for first-line care.
Risks
- Acute panic and paranoia from high-THC products, especially edibles and concentrates. SAD patients appear more vulnerable Strong evidence [4][6].
- Cannabis use disorder. People who use cannabis to cope with social anxiety develop CUD at higher rates than recreational users Strong evidence [5].
- Worsening anxiety over time with regular heavy use Strong evidence [5].
- Drug interactions. CBD at therapeutic doses (hundreds of mg) inhibits CYP2C19, CYP2C9, and CYP3A4, potentially raising levels of SSRIs, benzodiazepines, and other psychiatric medications Strong evidence [8]. Do not combine without a prescriber's review.
- Avoidance reinforcement. Using cannabis to get through social situations can short-circuit the exposure that CBT relies on to actually treat SAD. This is mechanism-level, not directly trialed, but consistent with anxiety-disorder theory. Weak / limited
Sources
- Government National Institute of Mental Health. Social Anxiety Disorder. NIMH Statistics, accessed 2024. ↗
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
- Peer-reviewed Zuardi AW, Rodrigues NP, Silva AL, et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Frontiers in Pharmacology. 2017;8:259.
- Peer-reviewed Childs E, Lutz JA, de Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. 2017;177:136-144.
- Peer-reviewed Buckner JD, Heimberg RG, Schmidt NB. Social anxiety and marijuana-related problems: the role of social avoidance. Addictive Behaviors. 2011;36(1-2):129-132.
- Peer-reviewed Buckner JD, Schmidt NB, Lang AR, et al. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. Journal of Psychiatric Research. 2008;42(3):230-239.
- Peer-reviewed Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Frontiers in Psychology. 2019;10:2466.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368-376.
- Peer-reviewed Williams T, Hattingh CJ, Kariuki CM, et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database of Systematic Reviews. 2017;10:CD001206.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Generalized Anxiety Disorder — What the evidence actually says about using cannabis, CBD, and THC for chronic, persistent...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...